Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

A variety of approaches to measure the efficacy of PARP inhibitors

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.04.18
Views: 648

Dr Elisabetta Leo - AstraZeneca, Cambridge, UK

Dr Leo speaks with ecancer at AACR 2018 about results from a head-to-head comparison of five PARP inhibitors using a novel proteomic assay.

Having compared the approvals, mechanisms and doses of olaparib, veliparib, rucaparib, niraparib and talazoparib, Dr Leo highlights the potential for predicting responses and assessing novel PARP inhibitors.

For more on PARP inhibitors, watch our interview with Dr Mark O’Connor here.

Related videos

follow us

NCRI 2018


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation